Incruse Ellipta (Umeclidinium Bromide)

Umeclidinium bromide selectively blocks muscarinic M3 receptors on airway smooth‑muscle cells. By preventing acetylcholine‑induced bronchoconstriction, it produces sustained bronchodilation, allowing easier airflow and better lung function throughout the day.

The prescribed dose is determined by the treating physician. In clinical practice the inhaler is typically used once daily, but the exact regimen, including any dose adjustments, must follow the prescriber’s instructions.

Safety data for umeclidinium bromide in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Incruse Ellipta belongs to the long‑acting muscarinic antagonist (LAMA) class, similar to tiotropium. Both provide once‑daily bronchodilation, but differences in device design, inhalation resistance and specific pharmacokinetic profiles may influence patient preference and adherence.

Store the inhaler at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and extreme heat. Do not expose the device to freezing temperatures, and replace the inhaler after the indicated period once opened.

The patient inhales a single dose from the dry‑powder inhaler by breathing in quickly and deeply through the mouth, following the device’s instructions. No coordination with actuation is required, but the inhaler must be primed according to the manufacturer’s guidelines before first use.

Serious adverse events, although rare, include paradoxical bronchospasm, severe allergic reactions such as rash, angioedema or anaphylaxis, and urinary retention that may require medical attention. Patients should be instructed to seek immediate care if any of these symptoms occur.

Individuals with a known hypersensitivity to umeclidinium bromide or any excipients in the inhaler should avoid its use. Caution is also advised for patients with narrow‑angle glaucoma, urinary retention, or those taking other anticholinergic medications, and the decision should be guided by a clinician.